Item 8.01. Other Events.
On February 1, 2023, Sesen Bio, Inc. (the "Company") announced that the U.S.
District Court for the Southern District of New York (the "Court") issued an
order on January 31, 2023 granting final approval of the settlement of the
consolidated shareholder class action captioned In re Sesen Bio, Inc. Securities
Litigation, Master File No. 1:21-cv-07025-AKH (the "Securities Litigation"), in
accordance with the Stipulation and Agreement of Settlement that the Company
disclosed in a Current Report on Form 8-K dated August 17, 2022. As previously
disclosed in the Company's Current Report on Form 8-K dated September 29, 2022,
the Court issued an order on September 28, 2022 granting preliminary approval of
the settlement of the Securities Litigation.
Information concerning the settlement of the Securities Litigation was sent
directly to potential class members by the claims administrator and was posted
on a website (www.sesenbiosecuritiessettlement.com) developed for purposes of
providing information about the settlement. Information contained in or
accessible through that website does not constitute part of, and is not
incorporated into, this Current Report on Form 8-K.
The Company also disclosed in a Current Report on Form 8-K dated November 9,
2022, that the U.S. District Court for the District of Massachusetts granted
final approval of the settlement of the previously disclosed consolidated
derivative lawsuits captioned In re Sesen Bio, Inc. Derivative Litigation, Lead
Case No. 1:21-cv-11538, the derivative lawsuit captioned Tang v. Sesen Bio,
Inc., et al., Case No. 2281-cv-00135 and other potential related derivative
claims (collectively, the "Derivative Litigation"), in accordance with the
Stipulation of Settlement that the Company disclosed in a Current Report on Form
8-K dated August 30, 2022.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses